Aerovate Therapeutics (AVTE) Q4 2024 earnings summary

Executive summary

• Announced negative Phase 2b results for AV-101 in PAH, leading to halting all development and a 92% workforce reduction as of December 31, 2024.

• Entered into a merger agreement with Jade Biosciences, with a planned $65M cash dividend to pre-merger shareholders and a $300M concurrent investment by Jade investors.

• Company does not intend to resume AV-101 or any other product development; future operations depend on the successful completion of the merger.

Financial highlights

• Net loss for 2024 was $69.6M, compared to $75.5M in 2023; accumulated deficit reached $233.1M.

• Research and development expenses decreased to $53.2M in 2024 from $64.2M in 2023, mainly due to lower clinical and manufacturing costs.

• General and administrative expenses increased to $21.4M in 2024, up $4.2M year-over-year, driven by legal, consulting, and severance costs.

• Cash, cash equivalents, and short-term investments totaled $78.6M as of December 31, 2024.

• At-the-market equity sales generated $67.9M in net proceeds during 2023–2024.

Outlook and guidance

• Existing cash and investments expected to fund operations for at least 12 months from the filing date.

• Future operations and capital needs are highly dependent on the completion of the merger with Jade; failure to close may result in liquidation.